

## **MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.**

Valentina La Rosa, Giovanna Poce, Julio Ortiz Canseco, Silvia Buroni, Maria Rosalia Pasca, Mariangela Biava, Ravikiran M Raju, Giulio Cesare Porretta, Salvatore Alfonso, Claudio Battilocchio, et al.

► **To cite this version:**

Valentina La Rosa, Giovanna Poce, Julio Ortiz Canseco, Silvia Buroni, Maria Rosalia Pasca, et al.. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.. *Antimicrobial Agents and Chemotherapy*, American Society for Microbiology, 2012, 56 (1), pp.324-31. 10.1128/AAC.05270-11 . pasteur-00968568

**HAL Id: pasteur-00968568**

**<https://hal-riip.archives-ouvertes.fr/pasteur-00968568>**

Submitted on 1 Apr 2014

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212

Valentina La Rosa, Giovanna Poce, Julio Ortiz Canseco, Silvia Buroni, Maria Rosalia Pasca, Mariangela Biava, Ravikiran M. Raju, Giulio Cesare Porretta, Salvatore Alfonso, Claudio Battilocchio, Babak Javid, Flavia Sorrentino, Thomas R. Ioerger, James C. Sacchettini, Fabrizio Manetti, Maurizio Botta, Alessandro De Logu, Eric J. Rubin and Edda De Rossi

*Antimicrob. Agents Chemother.* 2012, 56(1):324. DOI: 10.1128/AAC.05270-11.

Published Ahead of Print 24 October 2011.

---

Updated information and services can be found at:  
<http://aac.asm.org/content/56/1/324>

---

*These include:*

### REFERENCES

This article cites 22 articles, 6 of which can be accessed free at:  
<http://aac.asm.org/content/56/1/324#ref-list-1>

### CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), [more»](#)

---

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>  
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

# MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212

Valentina La Rosa,<sup>a</sup> Giovanna Poce,<sup>b,c</sup> Julio Ortiz Canseco,<sup>a</sup> Silvia Buroni,<sup>a</sup> Maria Rosalia Pasca,<sup>a</sup> Mariangela Biava,<sup>c</sup> Ravikiran M. Raju,<sup>b</sup> Giulio Cesare Porretta,<sup>c</sup> Salvatore Alfonso,<sup>c</sup> Claudio Battilocchio,<sup>c</sup> Babak Javid,<sup>b</sup> Flavia Sorrentino,<sup>b</sup> Thomas R. Ioerger,<sup>e</sup> James C. Sacchettini,<sup>e</sup> Fabrizio Manetti,<sup>d</sup> Maurizio Botta,<sup>d</sup> Alessandro De Logu,<sup>f</sup> Eric J. Rubin,<sup>b</sup> and Edda De Rossi<sup>a</sup>

Dipartimento di Genetica e Microbiologia, Università degli Studi di Pavia, Pavia, Italy<sup>a</sup>; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA<sup>b</sup>; Istituto Pasteur Fondazione Cenci-Bolognietti, Dipartimento di Chimica e Tecnologie del Farmaco, Università La Sapienza, Rome, Italy<sup>c</sup>; Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Siena, Italy<sup>d</sup>; Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA<sup>e</sup>; and Dipartimento di Scienze e Tecnologie Biomediche, Sezione di Microbiologia Medica, Università di Cagliari, Cagliari, Italy<sup>f</sup>

The 1,5-diarylpyrrole derivative BM212 was previously shown to be active against multidrug-resistant clinical isolates and *Mycobacterium tuberculosis* residing within macrophages as well as against *Mycobacterium avium* and other atypical mycobacteria. To determine its mechanism of action, we identified the cellular target. Spontaneous *Mycobacterium smegmatis*, *Mycobacterium bovis* BCG, and *M. tuberculosis* H37Rv mutants that were resistant to BM212 were isolated. By the screening of genomic libraries and by whole-genome sequencing, we found that all the characterized mutants showed mutations in the *mmpL3* gene, allowing us to conclude that resistance to BM212 maps to the MmpL3 protein, a member of the MmpL (*mycobacterial membrane protein, large*) family. Susceptibility was unaffected by the efflux pump inhibitors reserpine, carbonyl cyanide *m*-chlorophenylhydrazone, and verapamil. Uptake/efflux experiments with [<sup>14</sup>C]BM212 demonstrated that resistance is not driven by the efflux of BM212. Together, these data strongly suggest that the MmpL3 protein is the cellular target of BM212.

The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) *Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB), makes the validation of new antitubercular agents a major global priority. Since tubercular drug resistance is chromosomally encoded (17), chemotherapeutic agents directed against new cellular targets are likely to be effective against both drug-sensitive and drug-resistant *M. tuberculosis* strains (5, 12, 13, 18). Target identification and validation are usually achieved by either genetic or chemical approaches. The former has the advantage of identifying a likely cellular target *a priori* but yields no information with regard to the druggability of the target and the access of the drug to the target (a particular problem in mycobacteria [23]). It is therefore not surprising that no current antitubercular agents have been identified through rational drug design (23). Alternatively, the identification of a cellular target candidate through chemical screening has the advantage of knowing that the compound can bind and affect the cellular target *in vivo*. The identification of the target for an active compound allows the rational modification of lead candidates through medicinal chemistry while ensuring that the compound retains activity against its primary target. However, finding which proteins are inhibited by a compound can be quite challenging.

We randomly screened a library of compounds to identify structures of interest for further development. Several azole compounds containing imidazole, pyrrole, toluidine, or methanamine groups were tested for antimycobacterial activity. Among them, 1-[1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl]methyl-4-methylpiperazine (BM212) (Fig. 1) proved to be active against multidrug-resistant clinical isolates, against *M. tuberculosis* residing within macrophages, and against *Mycobacterium avium* as well as other nontuberculous mycobacteria (7). The identification of BM212 as a hit within this compound class provided the stimulus to develop novel structures that could be endowed with less toxic features and better activities (3, 4).

Having identified a group of related compounds with potent antimycobacterial activity, we proceeded to identify the cellular target of BM212 as the prototype compound in its class. Here, by complementary genetic approaches, we propose that the MmpL3 protein is the cellular target for BM212.

## MATERIALS AND METHODS

**Synthesis of BM212.** All chemicals were used at a purity of >95%. A Discovery Microwave System apparatus (from CEM Corporation) was used for Stetter and Paal-Knorr reactions. Melting points were determined with open capillaries on a Gallenkamp apparatus and are uncorrected. Microanalyses were conducted with a Perkin-Elmer 240C or a Perkin-Elmer series II CHNS/O Analyzer 2400 instrument. Fluka silica gel 60 (230 to 400 mesh) was used for column chromatography. Fluka TLC plates (silica gel 60 F254) were used for thin-layer chromatography (TLC). Fluka aluminum oxide (activity II-III, according to the Brockmann scale) was used for chromatographic purifications. Fluka Stratocrom aluminum oxide plates with a fluorescent indicator were used for TLC to check the purity of the compounds. High-performance liquid chromatography (HPLC) analyses were conducted with a Waters Alliance 2695 instrument, using a UV-visible light (Vis) Waters PDA 996 detector and working at 333 nm. All synthesized compounds were ≥95% pure. <sup>13</sup>C nuclear magnetic resonance (NMR) and <sup>1</sup>H NMR spectra were recorded with a Bruker AC 400 spectrometer in CDCl<sub>3</sub> (with tetramethylsilane [TMS] as the internal standard).

Received 12 July 2011 Returned for modification 11 August 2011

Accepted 17 October 2011

Published ahead of print 24 October 2011

Address correspondence to Eric J. Rubin, erubin@hsph.harvard.edu, or Edda De Rossi, edda.derossi@unipv.it.

V. La Rosa and G. Poce contributed equally to the work.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.05270-11




FIG 1 Chemical structure of BM212. Me, methyl.

BM212 was synthesized as previously reported (3, 4). Briefly, 1-(4-chlorophenyl)pentane-1,4-dione was obtained by reacting the 4-Cl-benzaldehyde with methyl vinyl ketone. The resulting 1,4-diketone was cyclized in the presence of 4-Cl-aniline to yield 1,2-bis(4-chlorophenyl)-5-methyl-1H-pyrrole. BM212 was finalized by reacting 1,5-diarylpyrrole with formaldehyde and *N*-methylpiperazine under Mannich reaction conditions.

**DNA cloning and amplification.** The shuttle cosmid pYUB18 (12 kb) was used to construct genomic libraries (10). Primers YUB3 and YUB4 (Table 1), recognizing short sequences upstream and downstream of the BamHI restriction site, were utilized for the partial sequencing of genomic inserts. Subcloning experiments with one of the cosmids conferring BM212 resistance were performed by cloning into the pGEM-T Easy vector (Promega) and then into the final vectors pSUM39 (1) and pMD31 (9).

For several strains of *Mycobacterium bovis* BCG and *M. tuberculosis* H37Rv, results from whole-genome sequencing were confirmed by the cloning of the *mmpL3* gene into pBluescript, followed by the targeted resequencing of *mmpL3*.

All primers used for PCR amplification are listed in Table 1. Amplification reactions were performed with a final volume of 40  $\mu$ l containing 200  $\mu$ M each deoxynucleotide triphosphate (dNTP), 500 nM each primer, 2% dimethyl sulfoxide (DMSO), 2.5 mM MgCl<sub>2</sub>, 40 ng of plasmid

DNA or 100 ng of genomic mycobacterial DNA, and 1 U of *Pfu* DNA polymerase (Promega). Cycling conditions were as follows: denaturation at 95°C for 2 min, followed by 30 cycles of denaturation at 95°C for 1 min, annealing for 30 s at a temperature dependent on the primers used, and elongation at 72°C for a time dependent on the product size, with a final elongation step at 72°C for 5 min.

PCR products were blunted into pBluescript at the EcoRV site, and the *mmpL3* gene was sequenced by using primers listed in Table 1.

**Bacterial strains, media, and growth conditions.** *Escherichia coli* HB101 was used as a host strain and for the construction of genomic libraries; the *E. coli* XL1-Blue MRF' Tet<sup>r</sup> strain (Stratagene) was used for cloning procedures. These strains were grown in Luria-Bertani (LB) broth or on LB agar (20). Plates were supplemented, when required, with tetracycline (12.5  $\mu$ g/ml) (Sigma), ampicillin (50  $\mu$ g/ml) (Sigma), kanamycin (50  $\mu$ g/ml) (Sigma), and streptomycin (50  $\mu$ g/ml) (Duchefa Biochimie B.V.). All strains were grown aerobically at 37°C with shaking (200 rpm). The plates were incubated at 37°C for 1 day.

*Mycobacterium smegmatis* wild-type strain mc<sup>2</sup>155 and mutant strains MSMEG-GR12.5 and MSMEG-BM1 to MSMEG-BM10 (Table 2) were grown in Middlebrook 7H9 medium (Difco) supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC) enrichment broth (Difco) and 0.05% Tween 80 or on 7H11 agar (Difco) supplemented with 10% OADC and 0.5% glycerol. When required, kanamycin was added at a concentration of 25  $\mu$ g/ml. All cultures were grown aerobically at 37°C with shaking (200 rpm). The plates were incubated at 37°C for at least 3 days.

*M. smegmatis* wild-type strain mc<sup>2</sup>155 and mutant strains SRBM212\_20, SRBM212\_21, SRBM212\_24, and SRBM212\_26 (Table 2) were grown in Middlebrook 7H9 medium (Difco) supplemented with 10% albumin-dextrose-catalase (ADC), 0.05% Tween 80, and 0.2% glycerol or on 7H10 agar (Difco) supplemented with 10% ADC and 0.5% glycerol. All cultures were grown aerobically at 37°C with shaking (160 rpm). The plates were incubated at 37°C for at least 5 days.

*Mycobacterium bovis* wild-type strain BCG and mutants resistant to BM212, BCG-BM40 to BCG-BM44, and BCG-BM49 to BCG-BM56 (Table 3), were grown as described above for *M. smegmatis* at 37°C for about

TABLE 1 Oligonucleotides used in this work

Oligonucleotide	Sequence	Purpose
BM1	GTGGGCGGCATCCTGACCTTCGT	Sequencing of the <i>M. smegmatis</i> 5.2-kb Scal/EcoRV fragment containing the <i>mmpL3</i> gene
BM2	AACGCGCCAGCCAGGACTCG	
BM3	GCCGTGACATACCGCGTTCA	
BM4	GAATTGCTCCTGCGACTGGCG	
BM5	AAGTGCACGGGGTGAACCTCGG	
BM6	CCAGGCGAACACTTAGGCTC	
BM7	TTTCTCCGCGCCGACACCGT	
YUB3	GCAGATCCGCGCCAGATTC	pYUB18 cosmid sequencing
YUB4	TGGCGGCGGCACGTTTCATCA	
MMPLB1	GACGTGTGTGACAACCAAA	Sequencing of the <i>M. bovis</i> BCG <i>mmpL3</i> gene
MMPLB3	AACGGCGAATGGAAGTGCT	
MMPLB5	ATCCTGTCTATCACCGTGTG	
MMPLB7	ACCCCGCCAAAGGAATCAC	
MMPLB9	TCGGTGATGAAGCTGCTCGG	
Rv0206_seq1	GACGTGGTGGACAACCAAAAAG	Subcloning and sequencing of the <i>M. tuberculosis</i> <i>mmpL3</i> gene
Rv0206_seq2	GAATGGAAGTGCTGGCGC	
Rv0206_seq3	TCAGCGAGAAGTACTTGCC	
Rv0206_seq4	CATCATTACCGCCGCGCG	
Rv0206_seq5	AATCATAACGGTCCGACGGC	
Rv0206_PCRf	AGGACATCGCTGGTGTTTCCGG	
Rv0206_PCRr	GCTTTCCTCAACAATGCGGTGCA	

TABLE 2 MICs of BM212 and amino acid substitutions in the *mmpL3* gene of *M. smegmatis* mutants resistant to BM212<sup>a</sup>

<i>M. smegmatis</i> strain(s)	MIC ( $\mu\text{g/ml}$ )	Amino acid change (position)	Mutation(s) in another <i>M. smegmatis</i> ORF(s)
mc <sup>2</sup> 155 (wt)	3.125		
MSMEG-GR12.5	12.5	A254V I296L	
MSMEG-BM1, MSMEG-BM2, MSMEG-BM7, MSMEG-BM8	12.5	I249T	
MSMEG-BM3, MSMEG-BM4	12.5	F240L	
MSMEG-BM6	12.5	L196P	
MSMEG-BM9	12.5	A347V	
MSMEG-BM10	12.5	V689G	
SRBM212_20	25	A326T	
SRBM212_21	25	A326T	MSMEG_2883, T130T
SRBM212_24	25	V689G	MSMEG_0931c, +C; 3682514, T>C (noncoding); deletion of MSMEG_1716–MSMEG_1726
SRBM212_26	25	V197M	

<sup>a</sup> The different nomenclatures of strains refer to mutants isolated during different experiments (see Materials and Methods). wt, wild type.

3 to 4 weeks under static conditions, while plates were incubated at 37°C for at least 3 weeks.

Wild-type *M. bovis* BCG and *M. bovis* mutant strains BCGRBM212\_1 and BCGRBM212\_2 (Table 3) were also grown in Middlebrook 7H9 medium (Difco) supplemented with 10% ADC, 0.05% Tween 80, and 0.2% glycerol or on 7H10 agar (Difco) supplemented with 10% ADC and 0.5% glycerol at 37°C for about 10 days with shaking (160 rpm). The plates were incubated at 37°C for at least 4 weeks.

*M. tuberculosis* wild-type strain H37Rv and mutant strain TBRBM212\_1 (Table 3) were grown in Middlebrook 7H9 medium (Difco) supplemented with 10% OADC, 0.05% Tween 80, and 0.2% glycerol or on 7H10 agar (Difco) supplemented with 10% OADC and 0.5% glycerol at 37°C for approximately 3 weeks with shaking (160 rpm). The plates were incubated at 37°C for at least 8 weeks.

TABLE 3 MICs of BM212 and amino acid substitutions in the *mmpL3* genes of *M. bovis* BCG and *M. tuberculosis* H37Rv mutants resistant to BM212<sup>a</sup>

Strain(s)	MIC ( $\mu\text{g/ml}$ )	Amino acid change (position)
<i>M. bovis</i>		
BCG (wt)	0.78	
BCG-BM40	6.25	I250M L320P
BCG-BM41	6.25	T286K L320P
BCG-BM42, BCG-BM43, BCG-BM49, BCG-BM52–BCG-BM56	3.12	L320P
BCG-BM44	3.12	T277M L320P
BCG-BM50	3.12	A316T L320P
BCG-BM51	3.12	A294T L320P
BCGRBM212_1	20	L320P
BCGRBM212_2	20	V240A
<i>M. tuberculosis</i>		
H37Rv (wt)	1.5	
TBRBM212_1	25	L215S

<sup>a</sup> The different nomenclatures of strains refer to mutants isolated during different experiments (see Materials and Methods).

**Drug susceptibility tests.** MICs of compounds (BM212, isoniazid [INH], and pump inhibitors) for *M. smegmatis*, *M. bovis* BCG, and *M. tuberculosis* H37Rv strains were determined with both solid and liquid media.

For assays performed with solid media, 7H11 agar medium supplemented with 10% OADC and 0.5% glycerol was used to prepare plates containing 2-fold serial dilutions of BM212 dissolved in DMSO at a concentration ranging from 0.17 to 100  $\mu\text{g/ml}$ . Cell cultures were grown to an optical density at 600 nm ( $\text{OD}_{600}$ ) of 0.8 and diluted to a final concentration of  $2 \times 10^6$  CFU/ml. One microliter of the diluted culture was then streaked onto each plate and incubated at 37°C for 3 to 4 days, 4 to 5 weeks, or 8 weeks for *M. smegmatis*, *M. bovis* BCG, or *M. tuberculosis* H37Rv, respectively. The MIC was defined as the lowest concentration of drug that prevented the formation of colonies.

For assays performed with liquid media, the MIC was defined as the lowest concentration of drug that yielded an absence of visual turbidity. BM212 and INH, prepared in ethanol and sterile water, respectively, were dissolved in 3 ml of Middlebrook 7H9 medium, to a final concentration ranging from 0.125 to 100  $\mu\text{g/ml}$ , in 2-fold serial dilutions. The medium was then inoculated with mycobacteria to an  $\text{OD}_{600}$  of 0.003 of *M. smegmatis*, *M. bovis* BCG, or *M. tuberculosis* H37Rv and incubated at 37°C for 24 h, 10 days, or 12 days, respectively. A control tube or inkwell without any drug was included with each experiment, and INH was used as a control.

**Isolation of *M. smegmatis*, *M. bovis* BCG, and *M. tuberculosis* mutants resistant to BM212.** *M. smegmatis* mutant strains MSMEG-GR12.5 and MSMEG-BM1 to MSMEG-BM10 (Table 2), resistant to BM212, were isolated by plating about  $10^{10}$  cells on 7H11 solid medium containing a gradient of the compound (21) as well as with different concentrations of BM212, ranging from 3.125 to 100  $\mu\text{g/ml}$ . *M. bovis* mutant strains BCG-BM40 to BCG-BM44 and BCG-BM49 to BCG-BM56 (Table 3), resistant to BM212, were also isolated by plating about  $10^{10}$  cells onto 7H11 solid medium with concentrations of BM212 ranging from 3.125 to 100  $\mu\text{g/ml}$ .

*M. smegmatis* SRBM212\_20, SRBM212\_21, SRBM212\_24, and SRBM212\_26 (Table 2); *M. bovis* BCGRBM212\_1 and BCGRBM212\_2; and *M. tuberculosis* TBRBM212\_1 (Table 3), resistant to BM212, were isolated as follows. For *M. smegmatis* mc<sup>2</sup>155,  $5 \times 10^8$  CFU/ml was plated onto 7H10 medium containing different concentrations of BM212, ranging from 0.1 to 30  $\mu\text{g/ml}$ . For *M. bovis* BCG,  $5 \times 10^8$  CFU/ml was plated onto 7H10 agar containing concentrations of BM212 ranging from 3 to 10  $\mu\text{g/ml}$ . For *M. tuberculosis* H37Rv,  $5 \times 10^8$  CFU/ml was plated onto 7H10 agar containing concentrations of BM212 ranging from 2 to 10  $\mu\text{g/ml}$ .

Control 7H10 plates containing 30  $\mu\text{g/ml}$  of INH inoculated with either  $5 \times 10^8$  CFU/ml of *M. smegmatis* mc<sup>2</sup>155,  $5 \times 10^8$  CFU/ml of *M. bovis* BCG, or  $5 \times 10^8$  CFU/ml of *M. tuberculosis* H37Rv were used. The plates were incubated at 37°C for 7 days in the case of *M. smegmatis*, 4 weeks for *M. bovis* BCG, and 8 weeks for *M. tuberculosis* H37Rv.

**MIC determinations in the presence of efflux inhibitors.** The MICs of the efflux pump inhibitors reserpine (RES) (a plant alkaloid known to inhibit the transport of drugs extruded by ATP-energized pumps), carbonylcyanide *m*-chlorophenylhydrazone (CCCP) (a proton uncoupler), and verapamil (VER) (a calcium channel blocker) were determined for *M. smegmatis* mc<sup>2</sup>155. The susceptibilities of *M. smegmatis* strains mc<sup>2</sup>155, MSMEG-GR12.5, and SRBM212\_20 to BM212 were then tested in the presence of subinhibitory concentrations of CCCP (7.5  $\mu\text{g/ml}$ ), RES (12  $\mu\text{g/ml}$ ), and VER (40  $\mu\text{g/ml}$ ). The MICs of the pump inhibitors alone or in the presence of BM212 were determined in liquid medium, as reported above.

**Whole-genome sequencing.** Resistant mutants selected for whole-genome sequencing were sequenced with an Illumina GenomeAnalyzer II instrument in the paired-end mode with 51-bp reads. Genomic DNA was extracted from log-phase cultures by using a MasterPure purification kit (Illumina) according to the manufacturer's instructions. A total of 2 to 3  $\mu\text{g}$  of DNA for each sample was sheared by using a Covaris sonicator, and the standard Illumina sample preparation procedure was followed, including blunt-end repair, adapter ligation, PCR amplification, and size selection of 350- to 450-bp fragments on a 2% agarose gel, as described by the manufacturer (Multiplexing SamplePrep guide 1005361\_D; Illumina). Samples were loaded onto a flow cell, clusters were generated by using a ClusterStation instrument, sequencing by synthesis was carried out using TruSeq kit v.5, and images were collected and analyzed by using Illumina Offline Basecaller v1.8. Each data set, consisting of  $\sim 10$  million pairs of 51-bp reads, was aligned to the genome sequence of the parental strain (allowing up to 2 mismatches per read with no gaps, requiring paired reads to map within 500 bp of each other), and polymorphisms (single-nucleotide polymorphisms [SNPs] and indels) were identified by using software developed at Texas A&M University.

**[<sup>14</sup>C]BM212 accumulation.** The accumulation of BM212 was evaluated with wild-type *M. smegmatis* mc<sup>2</sup>155 and mutant strain MSMEG-GR12.5. Mycobacterial cells were grown to an OD<sub>600</sub> of 0.5 to 0.8 in 90 ml of 7H9 medium supplemented with Tween 80 and 0.2% glycerol. Cells were then washed twice at 5,000 rpm for 20 min with 10 ml 0.1 M phosphate buffer (pH 8.0) and resuspended in 4 ml of the same buffer containing 1 mM MgSO<sub>4</sub> and 0.2% glycerol. After incubation at 37°C for 15 min at 200 rpm, the assay was started by addition of the radiolabeled [<sup>14</sup>C]BM212 (0.25 mCi/ml) (Vitrox) at a final concentration of 1.9  $\mu\text{M}$  to the culture, and the culture was again incubated at 37°C with gentle shaking. At various time points, 50  $\mu\text{l}$  of the suspension (in duplicate) was removed, diluted in 1 ml of 0.1 M chilled phosphate buffer containing 0.1 M LiCl, and filtered through 0.45- $\mu\text{m}$ -pore-size filters (Millipore). The filters were washed twice with 5 ml of the same buffer, and the radioactivity retained on the filter was determined with a Perkin-Elmer Trilux MicroBeta 1450 Counter by using an Ecolume scintillation cocktail (ICN Biomedicals). The efflux experiment was repeated three times.

## RESULTS

**Isolation of *M. smegmatis*, *M. bovis* BCG, and *M. tuberculosis* H37Rv mutant strains resistant to BM212.** The MIC of BM212 against different mycobacterial species was evaluated as described in Materials and Methods. BM212 showed good potency against all mycobacterial species tested, as previously described (3, 4, 7) (Tables 2 and 3).

We isolated and characterized mycobacterial strains resistant to BM212 in order to identify the cellular target of BM212. The plating of *M. smegmatis* onto solid media containing various concentrations of BM212 yielded multiple isolates that exhibited higher MICs of BM212 than the parent strain (Table 2). The MIC

of BM212 for wild-type *M. smegmatis* strain mc<sup>2</sup>155 was 3.12  $\mu\text{g/ml}$  (Table 2). Mutants arose at a frequency of  $3.7 \times 10^{-7}$ . Fourteen out of 61 resistant isolates were characterized and showed MIC values ranging from 12.5 to 25  $\mu\text{g/ml}$ , 4- to 8-fold higher than those for the parent strain (Table 2). Isolates of the vaccine mycobacterial strain *M. bovis* BCG and *M. tuberculosis* H37Rv that were resistant to BM212 were selected by using a similar strategy. The MICs of BM212 for wild-type *M. bovis* BCG and *M. tuberculosis* H37Rv were 0.78 and 1.5  $\mu\text{g/ml}$ , respectively (Table 3). Fifteen out of 18 resistant isolates of *M. bovis* BCG were characterized and showed MIC values ranging from 3.12 to 20  $\mu\text{g/ml}$ , 4- to 25-fold higher than those for the parent strain (Table 3). The MIC of BM212 for the only resistant *M. tuberculosis* strain was 20  $\mu\text{g/ml}$ , 10-fold the MIC for the parent strain (Table 3). Mutants were isolated at frequencies of  $1.7 \times 10^{-8}$  for *M. bovis* and  $2 \times 10^{-9}$  for *M. tuberculosis*.

**Screening of cosmid libraries derived from BM212-resistant *M. smegmatis* isolates identified mutations in the *mmpL3* gene as mediating resistance to BM212.** Genomic DNAs from two BM212-resistant isolates of *M. smegmatis*, MSMEG-GR12.5 and MSMEG-BM10, were used to construct two cosmid libraries by using vector pYUB18 (10) and were transformed into *E. coli* cells. The isolated cosmid DNA was transformed into wild-type *M. smegmatis* mc<sup>2</sup>155 cells by electroporation, and the transformants were plated onto selective medium containing BM212 at concentrations ranging from 3.12  $\mu\text{g/ml}$  to 50  $\mu\text{g/ml}$ . Resistant colonies were first validated to ensure that they were truly resistant to BM212. The MIC of BM212 for isolated colonies was 12.5  $\mu\text{g/ml}$ , i.e., 4-fold the MIC for the same strain transformed with vector pYUB18. Cosmid DNA was extracted from the resistant clones and retransformed into *M. smegmatis* mc<sup>2</sup>155 to confirm that resistance was due to the cosmid and not to the generation of spontaneous resistance. As expected, all the cosmids conferred resistance to BM212.

The cosmids responsible for the resistance phenotype were partially sequenced, and sequences were compared with those of *M. smegmatis* mc<sup>2</sup>155 by using BlastN (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). All cosmids that mediated resistance contained a partially overlapping fragment. The cosmid derived from the screening of the genomic library from the resistant isolate MSMEG-GR12.5 contained a 22-kb genomic DNA insert with 2 partial genes and 16 intact genes. This fragment was digested with restriction enzymes and further subcloned into vectors pMD31 and pSUM39. Transformants containing these plasmids were again screened for resistance to BM212. A 5.2-kb *ScaI*/*EcoRV* fragment was found to confer resistance to BM212 and contained three genes, MSMEG\_0249 (1,140 bp), MSMEG\_0250 (3,042 bp), and MSMEG\_0251 (699 bp), which code for an integral membrane protein, the MmpL3 protein, and a hypothetical protein, respectively. The cloned DNA was sequenced, and the sequence was compared with the reference *M. smegmatis* genome. While the sequences for MSMEG\_0249 and MSMEG\_0251 were identical to the wild-type sequence, the *mmpL3* sequence contained 2 nonsynonymous mutations compared with the reference sequence. These encoded amino acid substitutions from alanine to valine at position 254 (A254V) and from isoleucine to leucine at position 296 (I296L) (Table 2).

For the cosmid derived from the screening of the genomic library from the resistant isolate MSMEG-BM10, a single muta-




FIG 2 Predicted topology of MmpL3 from *M. smegmatis* (MSMEG\_0250) (A) and *M. bovis* BCG (BCG0243c) (B). The arrows indicate the amino acid substitutions observed for *M. smegmatis* (A) (see also Table 2) and *M. bovis* (B) (see also Table 3) mutants resistant to BM212. The amino acid substitution observed for the only resistant *M. tuberculosis* mutant is highlighted in gray. The MEMSAT2 program was used to predict topology (11).

tion rendering an amino acid substitution from valine to glycine at position 689 (V689G) in the *mmpL3* gene was found (Table 2).

Given the results achieved with the screening of cosmid libraries, the *mmpL3* genes from the other nine resistant *M. smegmatis* mutants (MSMEG-BM1 to MSMEG-BM9) were amplified and sequenced. The analysis of these sequences revealed point mutations which caused an amino acid change for each mutant tested (Table 2). Altogether, these results suggest that mutations in the *mmpL3* gene

are responsible for BM212 resistance. As shown in Fig. 2A, the majority of these amino acid changes map within the first six transmembrane segments of the predicted MmpL3 topology.

**Whole-genome sequencing of resistant isolates to identify mutations responsible for BM212 resistance.** Among isogenic mutants resistant to BM212, the isolates with the highest MICs, SRBM212\_20, SRBM212\_21, SRBM212\_24, and SRBM212\_26 (Table 2), were selected for whole-genome sequencing to identify

polymorphisms linked with resistance. We used an Illumina GenomeAnalyzer instrument with 51-bp reads in the paired-end mode, yielding a mean depth of coverage of 50× to 78× (number of reads covering each nucleotide) and a completion of >99.9% (fraction of sites covered by at least one read). Compared to the genome sequence of the parental strain *M. smegmatis* mc<sup>2</sup>155, each strain was observed to have a nonsynonymous substitution in the *mmpL3* gene (MSMEG\_0250), including the mutations A326T, V689G, and V197M (Table 2). As shown in Fig. 2A, the first and the second of these amino acid changes map to transmembrane segments, while the last one lies within a cytoplasmic domain of the predicted MmpL3 topology.

For two of the strains, these were the only polymorphisms detected in the entire genome. The other two strains had additional polymorphisms, although one was synonymous (MSMEG\_2883, T130T), one was in a noncoding region, and one was a frameshift mutation in a hypothetical protein (MSMEG\_0931c) (Table 2). Strain SRBM212-24 also had an 8,566-bp deletion of MSMEG\_1716 to MSMEG\_1726 (6 open reading frames [ORFs] of which are annotated as transposases and 3 of which are annotated as hypothetical proteins) (Table 2). These results strongly suggest that mutations in *mmpL3* confer resistance to BM212.

**BM212-resistant isolates of *M. bovis* BCG and *M. tuberculosis* H37Rv contain mutations in *mmpL3*.** Given the identification of mutations in *mmpL3* as likely to be responsible for resistance to BM212 in *M. smegmatis*, we determined the sequence of *mmpL3* from the BM212-resistant *M. bovis* BCG and *M. tuberculosis* isolates. Of note, all the resistant *M. bovis* BCG isolates had a common mutation in *mmpL3* that resulted in a change from leucine to proline at position 320 (L320P) (Table 3). Some of the BCG isolates also had a second nonsynonymous mutation within the *mmpL3* gene (Table 3). As shown in Fig. 2B, the majority of these amino acid changes map within the first six transmembrane segments of the predicted topology. The mutation identified in the *mmpL3* gene of the resistant *M. tuberculosis* strain results in a change from leucine to serine at position 215 (L215S) (Table 3) in the third transmembrane segment of the predicted MmpL3 topology (Fig. 2B).

**Mutations in *mmpL3* do not mediate resistance to BM212 via drug efflux.** MmpL3 encodes one of the MmpL (*mycobacterial membrane protein, large*) proteins, a family that has primary structure homology to the resistance-nodulation-cell division (RND) protein family, a group of proteins that are mainly involved in drug resistance in Gram-negative bacteria (16). Since energy-dependent bacterial efflux pumps can confer a multidrug resistance phenotype to clinically important pathogens by extruding the drug out of the cell before it can reach its target, we felt that it was important to exclude the possibility that resistance to BM212 mediated by mutations in the *mmpL3* gene is due to the efflux of the compound.

We investigated whether the resistance phenotype could be modified by broadly acting efflux pump inhibitors. We tested three well-characterized MDR pump inhibitors; none of them changed the susceptibility of resistant *M. smegmatis* isolates to BM212 (Table 4), suggesting that mutations in the *mmpL3* gene did not cause resistance via drug efflux.

We also excluded the possibility that resistance to BM212 might be due to the overexpression of the *mmpL3* gene. Quantitative PCR of *mmpL3* transcripts from both wild-type and BM212-resistant *M. smegmatis* strains, in both the presence and

TABLE 4 MICs of BM212 for *M. smegmatis* strains grown in the presence of efflux pump inhibitors

Compound	MIC ( $\mu\text{g/ml}$ ) <sup>a</sup>		
	<i>M. smegmatis</i> mc <sup>2</sup> 155	MSMEG_GR12.5	SRBM212_20
Reserpine	>240	>240	>240
CCCPC	30	30	NT
Verapamil	>100	>100	>100
BM212	3	12.5	25
BM212 + reserpine	3	12.5	25
BM212 + CCCPC	3	12.5	25
BM212 + verapamil	3	12.5	25

<sup>a</sup> NT, not tested.

the absence of BM212, revealed no difference in *mmpL3* expression (data not shown).

To further determine whether resistant *M. smegmatis* strains extruded BM212 out of the cell, we formally tested the accumulation and efflux of [<sup>14</sup>C]BM212 in both wild-type and BM212-resistant (MSMEG-GR12.5) *M. smegmatis* strains (Fig. 3). [<sup>14</sup>C]BM212 accumulated in both strains rapidly within 5 min, at which time concentrations remained constant for the following 60 min (Fig. 3). There was no difference in the rate or quantity of BM212 accumulation between wild-type and BM212-resistant strains. Taken together, these data strongly suggest that the mechanism of resistance to BM212 mediated by *mmpL3* mutations is not via drug efflux.

## DISCUSSION

All antibiotics in current usage were identified through the traditional screening of small-molecule libraries for activity against bacteria. Only subsequently was the cellular target(s) of the drug identified, sometimes decades after the agent entered clinical use. In some cases, such as with the first-line antitubercular agent isoniazid, the identification of the cellular target proved difficult and controversial (2, 14, 19), and in others, such as with metronidazole, the target(s) remains elusive.

The alternative to whole-cell-based screens, target-based screening, has failed to live up to expectations, at least for antibiotic development (15). Nonetheless, knowing the target of a hit compound greatly facilitates the process of progressing from hit to lead compound to clinical agent.

In this study, by complementary genetic approaches, we identified mutations in the *mmpL3* gene (MSMEG\_0250, BCG0243c, and Rv0206c) as being responsible for resistance to BM212, a novel candidate antitubercular agent. We also provided evidence that resistance to BM212 from mutations in the *mmpL3* gene are not due to an enhanced efflux of the drug, making it likely that the *mmpL3* gene product is the cellular target for BM212 activity.

One point mutation was identified in 11 out of 14 characterized *M. smegmatis* mutants resistant to BM212, giving rise to similar levels of resistance (4- to 8-fold the MIC for the wild-type strain). These mutations are localized at different nucleotide positions, but the majority map to the first six transmembrane segments of the predicted MmpL3 topology. Two independent mutants (MSMEG-BM10 and SRBM212\_26) contain the same amino acid change, V689G; the latter strain additionally contains an 8,566-bp deletion and two other mutations. As this deleted region contains genes coding for hypothetical proteins, trans-






FIG 3 [<sup>14</sup>C]BM212 accumulation by *M. smegmatis* wild-type and *M. smegmatis* MSMEG-GR12.5 cells. [<sup>14</sup>C]BM212 was added to the cells at time zero. The results are the averages of data from three experiments, and error bars indicate standard deviations.

posases, and pseudogenes, as annotated by SmegmaList (<http://mycobrowser.epfl.ch/smegmalist.html>), it seems unlikely that this deletion is responsible for resistance, although further experiments would be necessary to clarify the role of this large deletion in resistance to BM212.

Two SNPs were identified in the *mmpL3* gene in 5 out of 15 characterized *M. bovis* isolates resistant to BM212. One mutation, encoding the L320P change, occurs individually in nine other *M. bovis* mutants with small differences in the BM212 MIC values. This finding suggests that the L320P SNP is important for conferring BM212 resistance and that the second SNP observed for other mutants (I250M, T286K, T277M, A316T, and A294T) does not contribute to BM212 resistance. Also, in *M. bovis*, like *M. smegmatis*, the majority of these amino acid changes map to the first six transmembrane segments of the predicted MmpL3 topology. The only *M. tuberculosis* mutant resistant to BM212 presented the SNP L215S in the third transmembrane segment.

Since no good structural model of a close homologue of MmpL3 with significant sequence identity (>40%) is available, it is difficult to determine how the mutations that mediate resistance could alter the association of the protein with BM212. However, the fact that the mutated amino acids all lie within predicted transmembrane segments is not surprising given the hydrophobicity of the compound. However, if these amino acids do interact directly with the compound, BM212 might well inhibit MmpL3's ability to act as a transporter.

It is noteworthy that we found a higher frequency of resistance in *M. smegmatis* than in both *M. bovis* BCG and *M. tuberculosis*. One possible explanation for this finding is that mutations in *M. smegmatis mmpL3* are better tolerated, as *mmpL3* appears to be essential in *M. tuberculosis* (22).

MmpL3 is a putative membrane protein belonging to the RND protein family of multidrug resistance pumps that mediate the transport of a diverse array of ionic or neutral compounds as well as heavy metals and fatty acids (16). The *M. tuberculosis* genome

encodes 13 members of the MmpL (*mycobacterial membrane protein, large*) family (6). Despite their annotation as multidrug transporters, they do not appear to play a role in antimycobacterial drug resistance (8). A recent report has ascribed a role for *mmpL3* in heme acquisition by *M. tuberculosis* (22), although that role appears to be dispensable *in vitro*, suggesting that MmpL3 may have other functions as well.

The use of high-throughput sequencing technologies in addition to classical genetics and biochemistry provides new opportunities for the rapid identification of likely targets for antibacterial agents. Our data suggest that the *mmpL3* gene product is likely the cellular target for BM212. This suggests that MmpL3 represents a new potential druggable target for the treatment of TB. Novel targets such as this are critical given the current epidemic of drug-resistant TB.

#### ACKNOWLEDGMENTS

This work was supported by the CARIPO Foundation (reference number 2006.0880/10.8485 Bando 2006), MIUR-PRIN 2008, and the Istituto Pasteur-Fondazione Cenci Bolognetti.

#### REFERENCES

1. Ainsa JA, Martin C, Cabeza M, De la Cruz F, Mendiola MV. 1996. Construction of a family of *Mycobacterium/Escherichia coli* shuttle vectors derived from pAL5000 and pACYC184: their use for cloning an antibiotic-resistance gene from *Mycobacterium fortuitum*. *Gene* 176:23–26.
2. Banerjee A, et al. 1994. *inhA*, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science* 263:227–230.
3. Biava M. 2002. BM212 and its derivatives as a new class of antimycobacterial active agents. *Curr. Med. Chem.* 9:1859–1869.
4. Biava M, et al. 2011. Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach. *ChemMedChem* 6:593–598.
5. Chan ED, Iseman MD. 2008. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. *Curr. Opin. Infect. Dis.* 21:587–595.
6. Cole ST, et al. 1998. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 393:537–544.
7. Deidda D, et al. 1998. Bactericidal activities of the pyrrole derivative BM

- 212 against multidrug-resistant and intramacrophagic *Mycobacterium tuberculosis* strains. *Antimicrob. Agents Chemother.* **42**:3035–3037.
8. Domenech P, Reed MB, Barry CE III. 2005. Contribution of the *Mycobacterium tuberculosis* MmpL protein family to virulence and drug resistance. *Infect. Immun.* **73**:3492–3501.
  9. Donnelly-Wu MK, Jacobs WR, Jr, Hatfull GF. 1993. Superinfection immunity of mycobacteriophage L5: applications for genetic transformation of mycobacteria. *Mol. Microbiol.* **7**:407–417.
  10. Jacobs WR, Jr, et al. 1991. Genetic systems for mycobacteria. *Methods Enzymol.* **204**:537–555.
  11. Jones DT, Taylor WR, Thornton JM. 1994. A model recognition approach to the prediction of all-helical membrane protein structure and topology. *Biochemistry* **33**:3038–3049.
  12. Lenaerts AJ, Degroote MA, Orme IM. 2008. Preclinical testing of new drugs for tuberculosis: current challenges. *Trends Microbiol.* **16**:48–54.
  13. Lienhardt C, Vernon A, Raviglione MC. 2010. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. *Curr. Opin. Pulm. Med.* **16**:186–193.
  14. Mdluli K, et al. 1998. Inhibition of a *Mycobacterium tuberculosis*  $\beta$ -ketoacyl ACP synthase by isoniazid. *Science* **280**:1607–1610.
  15. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. *Nat. Rev. Drug Discov.* **6**:29–40.
  16. Poole K. 2007. Efflux pumps as antimicrobial resistance mechanisms. *Ann. Med.* **39**:162–176.
  17. Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in *Mycobacterium tuberculosis*: 1998 update. *Tuber. Lung Dis.* **79**:3–29.
  18. Riccardi G, Pasca MR, Buroni S. 2009. *Mycobacterium tuberculosis*: drug resistance and future perspectives. *Future Microbiol.* **4**:597–614.
  19. Rozwarski D, Grant G, Barton D, Jacobs WR, Jr, Sacchettini JC. 1998. Modification of the NADH of the isoniazid target (InhA) from *Mycobacterium tuberculosis*. *Science* **279**:98–102.
  20. Sambrook J, Russell DW. 2001. *Molecular cloning: a laboratory manual*, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  21. Szybalski W, Bryson V. 1952. Genetic studies on microbial cross resistance to toxic agents. 1. Cross resistance of *Escherichia coli* to 15 antibiotics. *J. Bacteriol.* **64**:489–499.
  22. Tullius MV, et al. 2011. Discovery and characterization of a unique mycobacterial heme acquisition system. *Proc. Natl. Acad. Sci. U. S. A.* **12**:5051–5056.
  23. Wyatt PG, Gilbert IH, Read KD, Fairlamb AH. 2011. Target validation: linking target and chemical properties to desired product profile. *Curr. Top. Med. Chem.* **11**:1275–1283.